Physician profile
Melissa L F Knuckles
NPI 1821074360
$1,463,206.64
in general payments reported to CMS, 2019-2025
42 companies · $245K in 2025
The $245K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259K · 2020: $96K · 2021: $181K · 2022: $219K · 2023: $249K · 2024: $215K · 2025: $245K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $493K · Consulting Fee: $98K · Travel and Lodging: $60K · Food and Beverage: $22K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $19K · Honoraria: $16K · Education: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $493,334.92 |
| Consulting Fee | $97,564.57 |
| Travel and Lodging | $60,258.96 |
| Food and Beverage | $21,654.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,360.00 |
| Honoraria | $16,030.87 |
| Education | $582.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $166,621.03 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Regeneron Healthcare Solutions, INC. | $165,475.27 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $154,589.60 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $150,825.64 | 2019-2025 | |
| Genzyme Corporation | $128,844.69 | 2019-2025 | |
| Leo Pharma INC. | $111,636.99 | 2020-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $105,613.95 | 2019-2025 | |
| Galderma Laboratories, L.P. | $92,023.05 | 2020-2025 | Aklief, Nemluvio, Twyneo |
| Amgen INC. | $90,725.62 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $60,291.27 | 2021-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43,677.22 | 2019-2025 | Siliq |
| Pfizer INC. | $40,480.05 | 2019-2025 | |
| Celgene Corporation | $31,268.63 | 2019 | |
| Dermavant Sciences, INC. | $26,867.40 | 2023-2024 | Vtama |
| Botanix Sb INC | $23,187.46 | 2025 | Sofdra |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $20,706.80 | 2023-2025 | Zoryve |
| Organon LLC | $17,737.90 | 2023-2025 | Vtama, Hadlima |
| Incyte Corporation | $15,636.37 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $8,197.85 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Epi Health, LLC | $3,646.37 | 2019-2022 | |
| Janssen Biotech, INC. | $2,667.88 | 2020-2025 | Tremfya, Stelara, Remicade |
| Vyne Pharmaceuticals INC. | $1,142.10 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.86 | 2022-2025 | Spevigo, Cyltezo |
| Sanofi-Aventis U.S. LLC | $172.33 | 2019 | |
| Genentech USA, INC. | $146.07 | 2019-2024 | Xolair |
| Almirall LLC | $126.35 | 2021-2023 | Klisyri |
| Taro Pharmaceuticals USA, INC. | $61.15 | 2019 | |
| Fresenius Kabi USA, LLC | $58.74 | 2023 | Idacio |
| Dermira, INC. | $50.22 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $47.36 | 2019 | |
| Sandoz INC. | $45.14 | 2023-2024 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $39.58 | 2024-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $36.86 | 2022 | |
| Mayne Pharma Commercial LLC | $33.61 | 2019 | |
| Encore Dermatology INC. | $33.01 | 2020 | |
| Biofrontera INC. | $28.56 | 2022 | |
| Journey Medical Corporation | $24.11 | 2023 | |
| Kyowa Kirin, INC. | $23.50 | 2022 | |
| Dusa Pharmaceuticals, INC. | $18.64 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.89 | 2024 | Ycanth |
| Cipher Pharmaceuticals US LLC | $17.52 | 2025 | Natroba, Spinosad |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Knuckles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.